You are here

Tecentriq Approved As First Immunotherapy for Breast Cancer

For Locally Advanced or Metastatic Triple-Negative Type Only

Roche’s cancer immunotherapy drug Tecentriq (atezolizumab), a PD-L1 inhibitor, has received its fifth FDA approval, for advanced triple-negative breast cancer. Before this decision, no immunotherapies had been approved for any form of breast cancer.

The approval is only for locally advanced or metastatic triple-negative breast cancer expressing PD-L1, the molecule that locks onto PD-1 receptors on the surface of T cells. The PD-L1/PD-1 “handshake” blocks T cells from attacking the tumor. The first drugs that were developed to prevent the handshake, such as Bristol-Myers Squibb’s nivolumab and Merck’s pembrolizumab, target PD-1. Tecentriq binds with PD-L1, preventing the T-cell-sidelining handshake.

Despite all of the attention that immunotherapies have received, they help only a minority of patients. Data on overall survival aren’t final, but at last report, the Tecentriq patients with PD-L1-positive tumors had a median overall survival of 25 months, compared to 15.5 months for chemo-only patients.

Although the FDA approval was based on progression-free survival and on the fact that patients with triple-negative breast cancer have essentially no options, continued approval for triple-negative breast cancer “may be contingent upon verification and description of clinical benefit in a confirmatory trial(s),” Genentech, the Roche division that developed Tecentriq, said in a statement.

The American Cancer Society projects that about 40,000 people in the U.S. will be diagnosed with triple-negative breast cancer in 2019.

Source: STAT, March 8, 2019

Recent Headlines

First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status